Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2007
Mitsuyasu et al1 described potential immunologic and virologic effects of interleukin 2 administered to patients with moderately advanced human immunodeficiency virus (HIV) infection. While no significant differences were seen in median HIV RNA levels at 60 weeks, we were interested in earlier HIV RNA levels between week 12 and 60. In addition to promoting lymphocyte proliferation, interleukin 2 has also been shown and in fact used in vitro experiments to promote the infection of cell cultures with HIV. This raises the question of whether treatment with interleukin 2 may disrupt initial virologic control by antiretroviral therapy.
Go R, Steigbigel R. Interleukin 2 and HIV RNA Levels. Arch Intern Med. 2007;167(19):2144–2145. doi:10.1001/archinte.167.19.2144-b
Customize your JAMA Network experience by selecting one or more topics from the list below.